- Home
- LUNG vs GNFT Comparison
LUNG vs GNFT Comparison
Compare LUNG & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- GNFT
- Stock Information
- Founded
- LUNG 1995
- GNFT 1999
- Country
- LUNG United States
- GNFT France
- Employees
- LUNG N/A
- GNFT N/A
- Industry
- LUNG Industrial Specialties
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUNG Health Care
- GNFT Health Care
- Exchange
- LUNG Nasdaq
- GNFT Nasdaq
- Market Cap
- LUNG 248.0M
- GNFT 249.0M
- IPO Year
- LUNG 2020
- GNFT 2019
- Fundamental
- Price
- LUNG $6.45
- GNFT $5.59
- Analyst Decision
- LUNG Strong Buy
- GNFT Strong Buy
- Analyst Count
- LUNG 7
- GNFT 1
- Target Price
- LUNG $13.71
- GNFT $13.00
- AVG Volume (30 Days)
- LUNG 210.4K
- GNFT 21.1K
- Earning Date
- LUNG 10-28-2024
- GNFT 09-19-2024
- Dividend Yield
- LUNG N/A
- GNFT N/A
- EPS Growth
- LUNG N/A
- GNFT N/A
- EPS
- LUNG N/A
- GNFT 0.47
- Revenue
- LUNG $76,583,000.00
- GNFT $86,225,222.00
- Revenue This Year
- LUNG $22.73
- GNFT $155.44
- Revenue Next Year
- LUNG $19.02
- GNFT N/A
- P/E Ratio
- LUNG N/A
- GNFT $11.74
- Revenue Growth
- LUNG 26.26
- GNFT 175.45
- 52 Week Low
- LUNG $5.46
- GNFT $2.97
- 52 Week High
- LUNG $14.84
- GNFT $6.05
- Technical
- Relative Strength Index (RSI)
- LUNG 32.80
- GNFT 62.71
- Support Level
- LUNG $6.56
- GNFT $5.12
- Resistance Level
- LUNG $7.47
- GNFT $5.84
- Average True Range (ATR)
- LUNG 0.38
- GNFT 0.32
- MACD
- LUNG -0.22
- GNFT 0.02
- Stochastic Oscillator
- LUNG 2.76
- GNFT 60.94
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.